Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Omeros' Epic IPO Voyage Could be Delayed by a Former CFO's Lawsuit

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

The Seattle biotech navigates the recession and resuscitates its IPO, but its former CFO is now a whistleblower and has erected a legal hurdle.

You may also be interested in...



Omeros Debuts With $68 Million IPO Despite Legal Hassles From Former CFO

Seattle biotech Omeros ended its first day of trading Oct. 8 at $8.73, down 13 percent after initially pricing its shares at $10, the low end of its expected range

Omeros Debuts With $68 Million IPO Despite Legal Hassles From Former CFO

Seattle biotech Omeros ended its first day of trading Oct. 8 at $8.73, down 13 percent after initially pricing its shares at $10, the low end of its expected range

Omeros Debuts With $68 Million IPO Despite Legal Hassles from Former CFO

Investors push the stock down on its first day, but the Seattle biotech now has cash to help get its late-stage pain compound to market.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

EU Sets New Date For Publication Of Delayed Pharma Revision Proposals

High Ambitions For EU DARWIN Platform After Delivery Of First RWE Studies

Two Firsts For Keytruda As NICE Says Yes To English Funding For Advanced Cervical Cancer

Shared Savings Legislation Could Increase Medicare Biosimilar Access

See All
UsernamePublicRestriction

Register

PS068695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By